The Ministry of Health has clarified that Lenacapavir, a long-acting injectable HIV prevention drug, will be offered free of charge at selected public health facilities across Kenya, dispelling earlier reports of a Ksh7,800 annual cost to patients.

• The Ksh7,800 annual cost refers to the estimated cost per patient to the health system, not a charge to individuals.
• Kenya received an initial consignment of 21,000 starter doses, with 12,000 continuation doses expected by April 2026 and an additional 25,000 doses from the United States Government.
• The drug is administered just twice a year and was approved by the U.S. Food and Drug Administration in June 2025 and endorsed by the World Health Organisation in July 2025.
• The rollout begins in March 2026, targeting 15 high-burden counties in Phase One, with subsequent phases expanding nationwide.